Jiangsu Hualv Biological Technology Co.Ltd. (300970) — Capital Reinvestment Ratio
Jiangsu Hualv Biological Technology Co.Ltd. (300970) has a Capital Reinvestment Ratio of 0.36x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥345.31 Million) in capital expenditures (CN¥123.12 Million). See Jiangsu Hualv Biological Technology Co.L free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Jiangsu Hualv Biological Technology Co.Ltd. Capital Reinvestment Ratio (2019–2025)
This chart tracks Jiangsu Hualv Biological Technology Co.Ltd.'s Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Jiangsu Hualv Biological Technology Co.Ltd. (2019–2025)
Year-by-year Capital Reinvestment Ratio for Jiangsu Hualv Biological Technology Co.Ltd. from 2019 to 2025. For live market cap and broader valuation context, see 300970 market cap overview.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.36x | CN¥345.31 Million | CN¥123.12 Million | ▼ -81.7% |
| 2024 | 1.95x | CN¥137.80 Million | CN¥268.22 Million | ▲ +44.7% |
| 2023 | 1.34x | CN¥166.67 Million | CN¥224.15 Million | ▼ -40.7% |
| 2022 | 2.27x | CN¥179.84 Million | CN¥407.91 Million | ▼ -7.7% |
| 2021 | 2.46x | CN¥83.08 Million | CN¥204.09 Million | ▲ +156.1% |
| 2020 | 0.96x | CN¥199.09 Million | CN¥190.96 Million | ▲ +108.3% |
| 2019 | 0.46x | CN¥213.96 Million | CN¥98.54 Million | — |